Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting

Rhea-AI Summary

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will present data from its Phase 1 clinical trial, NEON-1, focusing on ALPN-202 monotherapy at the ASCO Virtual Annual Meeting from June 4-8, 2021. The presentation titled 'First-in-human dose escalation of ALPN-202' will provide an update on the trial results, which involve a dual checkpoint inhibitor aimed at advanced malignancies. ALPN-202 has shown promising preclinical efficacy compared to conventional checkpoint inhibitors. The company also plans to initiate NEON-2, a combination study with a PD-1 inhibitor, within the year.

Positive

• Successful preclinical studies of ALPN-202 show superior efficacy in tumor models compared to checkpoint inhibition alone.
• NEON-1 clinical trial is currently enrolling participants, indicating advancement in the development stage.
• Plans to initiate NEON-2, a combination study of ALPN-202 and a PD-1 inhibitor, later this year.

Negative

• None.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an upcoming presentation on NEON-1, the company’s Phase 1 clinical trial of ALPN-202 monotherapy at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, scheduled to take place June 4-8, 2021.

Details of the poster presentation are as follows:

Presentation Title:		First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies
Session Title:		Developmental Therapeutics—Immunotherapy
Date Poster Available:		Friday, June 4th
Abstract Number:		2547

The meeting presentation will update the data shown in the abstract.

Full abstracts will be available on the ASCO meeting website on May 19^th, 2021 and a copy of the presentation will be available on June 4^th on the Scientific Publications page of Alpine’s website.

About ALPN-202

ALPN-202 is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor with the potential to improve upon the efficacy of combined checkpoint inhibition while limiting significant toxicities. Preclinical studies of ALPN-202 have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. NEON-1 (NCT04186637), a Phase 1 study of ALPN-202 in patients with advanced malignancies, is currently enrolling. Alpine also plans the initiation of NEON-2, a combination study of ALPN-202 and a PD-1 inhibitor, later this year.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is creating first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, the timing of and results from clinical trials and preclinical development activities, clinical and regulatory objectives and the timing thereof, expectations regarding the sufficiency of cash combined with the potential $75 million in pre-option exercise milestones payable under our option and license agreement with AbbVie to fund operations through 2023, the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our product candidates, our ability to achieve milestones in our collaboration with AbbVie, the progress and potential of our other ongoing development programs, the timing of our public presentations and potential publication of future clinical data, the efficacy of our clinical trial designs, anticipated enrollment in our clinical trials and the timing thereof, expectations regarding our ongoing collaborations, and our ability to successfully develop and achieve milestones in our development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including the impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our product candidates; our ongoing discovery and preclinical efforts may not yield additional product candidates; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

“Secreted Immunomodulatory Proteins,” “SIP,” “Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,” “vIgD” and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005033/en/

FAQ

What is the purpose of the NEON-1 clinical trial for ALPN-202?

The NEON-1 clinical trial aims to evaluate the safety and efficacy of ALPN-202 as a monotherapy in patients with advanced malignancies.

When will the results from the NEON-1 trial be presented?

The results will be presented during the ASCO Virtual Annual Meeting from June 4-8, 2021.

What is ALPN-202?

ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor designed to improve efficacy while limiting toxicities in cancer treatment.

What new studies are planned for ALPN-202?

Alpine Immune Sciences plans to initiate NEON-2, a combination study of ALPN-202 with a PD-1 inhibitor, later in 2021.

What are the implications of the preclinical results of ALPN-202?

The preclinical results suggest that ALPN-202 may provide better treatment outcomes in cancer patients compared to standard checkpoint inhibitors.